Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Operating Leases (2019 - 2025)

Ironwood Pharmaceuticals' Operating Leases history spans 7 years, with the latest figure at $9.9 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 19.78% year-over-year to $9.9 million; the TTM value through Dec 2025 reached $9.9 million, down 19.78%, while the annual FY2025 figure was $9.9 million, 19.78% down from the prior year.
  • Operating Leases for Q4 2025 was $9.9 million at Ironwood Pharmaceuticals, down from $10.5 million in the prior quarter.
  • Across five years, Operating Leases topped out at $19.9 million in Q1 2021 and bottomed at $9.9 million in Q4 2025.
  • The 5-year median for Operating Leases is $15.3 million (2023), against an average of $15.2 million.
  • The largest annual shift saw Operating Leases fell 8.24% in 2021 before it dropped 19.78% in 2025.
  • A 5-year view of Operating Leases shows it stood at $18.5 million in 2021, then decreased by 10.2% to $16.6 million in 2022, then decreased by 12.39% to $14.5 million in 2023, then fell by 15.4% to $12.3 million in 2024, then dropped by 19.78% to $9.9 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Operating Leases are $9.9 million (Q4 2025), $10.5 million (Q3 2025), and $11.1 million (Q2 2025).